Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Prospect Capital Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Prospect Capital Corporation trades at $2.22 (market cap $1.10B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 4.1× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 22.73% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PSEC | |
|---|---|---|
Market Cap | $4.49B | $1.10B |
Sector | Health | Financials |
52-Week High | $28.06 | $3.47 |
52-Week Low | $20.06 | $2.15 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 22.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Prospect Capital Corporation (PSEC) trades at $2.20, down 1.79% recently, with a bearish technical outlook. The stock shows mixed fundamentals with a low P/B ratio of 0.37 but concerning negative revenue and net income margins. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.16 exceeding the $0.1109 forecast. The company maintains regular dividend payments, recently completing a $328 million portfolio sale that generated a 4.8x return on investment.
PSEC presents a high-risk opportunity with its deep discount to NAV and 18%+ yield attracting income investors, but fundamental deterioration and analyst skepticism pose significant challenges. The bearish technical signals and negative cash flow trends suggest caution, while the company's shift toward first-lien lending may improve portfolio quality over time. Investment suitability depends on risk tolerance for BDC volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
